Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Transaminase. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Novel transaminase mutant CN113621592A enables 99% yield of L-glufosinate. Reduces cost and improves supply chain reliability for agrochemical intermediates.
Patent CN119823960B discloses mutants for L-glufosinate. Improves efficiency and purity for agrochemical intermediate manufacturing supply chains.
Patent CN110914417B reveals high-activity transaminase for chiral amine synthesis, offering cost reduction and supply chain reliability for pharmaceutical intermediates.
Patent CN105039450A reveals one-step enzymatic route. High purity, scalable process for reliable pharmaceutical intermediate supplier partners seeking significant cost reduction and efficiency.
Novel transaminase mutants for chiral amine production. Enhanced stability at 55°C and pH 10. Cost-effective biocatalysis for pharma intermediates.
Patent CN116064451B reveals high-activity transaminase mutant. Enables cost reduction in pharmaceutical intermediates manufacturing with scalable enzymatic processes.
Advanced enzymatic deracemization of L-glufosinate-ammonium via patent CN112410383B. Delivers superior purity and cost efficiency for global agrochemical supply chains.
Patent CN117070577A reveals dual-enzyme cascade for high-purity L-glufosinate. Enhances supply chain reliability and reduces manufacturing costs significantly.
Patent CN106399418A details a transaminase method for moxifloxacin side chain, offering high purity and cost reduction in pharma manufacturing.
Patent CN105734089A reveals enzymatic synthesis for pharmaceutical intermediates. Offers high optical purity and scalable production for global supply chains.
Patent CN108660122A details high-efficiency transaminase mutant for L-glufosinate-ammonium production offering significant supply chain and cost advantages for global agrochemical manufacturers.
Patent CN111411095B discloses a novel recombinant (R)-ω-transaminase mutant with high activity and stereoselectivity for efficient sitagliptin intermediate production, ensuring supply chain stability.
Patent CN112094856B discloses high-efficiency transaminase mutants for sitagliptin synthesis, achieving >99.95% e.e. and enabling significant cost reduction in API manufacturing.
Novel chemo-enzymatic route for diabetes drug intermediate offers high purity and scalable manufacturing solutions for global pharmaceutical supply chains efficiently.
Patent CN110129306A details immobilized transaminase for besifloxacin intermediates. Offers high purity, reusability, and scalable manufacturing solutions for global pharmaceutical supply chains.
Patent CN108893455A details a transaminase mutant for L-glufosinate-ammonium production. Achieves 98% yield and 99% ee. Ideal for agrochemical intermediate supply chains seeking cost reduction.
Patent CN104894148A details a high-efficiency omega-transaminase mutant for chiral amine synthesis, offering significant cost reduction and supply chain reliability for pharmaceutical intermediates.
Patent CN107686852B reveals a novel omega-transaminase route for moxifloxacin intermediates, offering high ee values and streamlined manufacturing for reliable pharmaceutical intermediate suppliers.
Patent CN114657164B reveals a novel enzymatic route for L-glufosinate, offering superior purity and cost efficiency for agrochemical intermediate supply chains.
Patent CN118374468B reveals mutant transaminase for high yield chiral amine intermediate production with improved stereoselectivity.